The Latin America rare diseases treatment market shows strong growth potential from USD 42.7 billion in 2025 to USD 95.6 billion by 2031 at a 14.2% CAGR, driven by rising prevalence, genomics advances, and regulatory incentives
SWOT Analysis
| Strengths | Weaknesses |
|---|---|
| Large treatment-naïve population (664 million people) enables fast clinical trial recruitment and diverse ethnic representation | Limited incentives for orphan drug production lead to low industry interest in patents and commercialization |
| Supportive policies like fast-track approvals and market exclusivity boost investment | Stringent cost-effectiveness thresholds (e.g., Brazil’s 3x GDP per capita/QALY) hinder therapy incorporation |
| Growing biopharma focus on gene therapies and precision medicine | High costs of therapies Small patient populations Complex regulatory landscape Low awareness and infrastructure gaps |
| Opportunities | Threats |
| Regional partnerships for research, tax exemptions, and customs waivers can accelerate orphan drug access | Affordability & reimbursement challenges |
| Expansion of digital diagnostics, AI, and patient advocacy to prioritize treatments | Regulatory fragmentation across countries |
| Emerging market advantages like lower trial competition | Persistent infrastructure limitations Uncertain access and adoption pathways Price controls and centralized purchasing limit budget for high-cost therapies Reimbursement challenges and price sensitivity constrain pricing power |